Search

Your search keyword '"Laroni, Alice"' showing total 22 results

Search Constraints

Start Over You searched for: Author "Laroni, Alice" Remove constraint Author: "Laroni, Alice" Language undetermined Remove constraint Language: undetermined
22 results on '"Laroni, Alice"'

Search Results

1. sj-docx-1-msj-10.1177_13524585221102918 – Supplemental material for Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

2. sj-pdf-1-msj-10.1177_1352458520971817 – Supplemental material for COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments

3. sj-pdf-1-msj-10.1177_1352458520971817 – Supplemental material for COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments

4. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

5. Additional file 2: of MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

6. Additional file 1: of MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

7. MSJ790390_supplementary_material – Supplemental material for Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

8. T-cell trafficking in the central nervous system

9. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL

14. Switch Strategies in RRMS: A Real-Life Multi Center Study

15. A real‐world study of alemtuzumab in a cohort of Italian patients

16. Effect of SARS-CoV-2 mRNA Vaccination in MS Patients Treated With Disease Modifying Therapies

17. Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

18. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

19. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy

20. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

21. A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study

22. Italian Alemtuzumab Study Group. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

Catalog

Books, media, physical & digital resources